| NCT Number | NCT06222164 |
| Lead Sponsor | Invivoscribe, Inc. |
| Conditions | Hematologic Diseases |
| Enrollment | 2,000 participants |
| Start Date | 2024-03-30 |
| Primary Completion | 2027-03-30 (estimated) |
| Study Completion | 2027-06-30 (estimated) |
| Updated on ClinicalTrials.gov | 2025-05-04 |